Alemtuzumab
Alemtuzumab (Campath) is an antibody that wipes out lymphocytes carrying the CD52 marker. It is approved for chronic lymphocytic leukaemia and is supplied in the US through a restricted distribution programme.
Overview
Alemtuzumab is a CD52-directed cytolytic antibody approved by the FDA in 2001 (accelerated) for fludarabine-refractory B-cell CLL, with full approval as a single agent for B-CLL after the CAM307 randomised trial against chlorambucil in previously untreated patients (297 randomised; longer progression-free survival on alemtuzumab). Profound lymphopenia brings cytomegalovirus reactivation and opportunistic infection, so prophylaxis and monitoring are mandatory. In the EU, MabCampath was authorised in 2001 and withdrawn in 2012 when the sponsor repositioned the molecule as Lemtrada for multiple sclerosis; Campath remains available for CLL through the US Campath Distribution Program. It is also used off label as lymphodepleting conditioning in stem cell transplantation.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas: how tumours escape and what closes the route · Lines of therapy.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2001 | B-cell chronic lymphocytic leukaemia (single agent) |
| EU | 2001 | B-CLL after fludarabine (MabCampath; authorisation withdrawn 2012) |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Alemtuzumab" OR ABSTRACT:"Alemtuzumab" OR TITLE:"Campath" OR ABSTRACT:"Campath" OR TITLE:"MabCampath" OR ABSTRACT:"MabCampath" OR TITLE:"Lemtrada multiple sclerosis formulation" OR ABSTRACT:"Lemtrada multiple sclerosis formulation") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Alemtuzumab, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductClofarabine
Shares Sanofi and the tag nci-list.
- ProductOfatumumab
Shares Monoclonal antibodies, Chronic lymphocytic leukaemia and the tag nci-list.
- ProductZiv-aflibercept
Shares Sanofi and the tag nci-list.
- ProductNecitumumab
Shares Monoclonal antibodies and the tag nci-list.
- ProductSiltuximab
Shares Monoclonal antibodies and the tag nci-list.
- ProductIbritumomab tiuxetan
Shares Monoclonal antibodies and the tag nci-list.
- ProductRasburicase
Shares Sanofi, Chronic lymphocytic leukaemia and the tag nci-list.
- ProductFludarabine
Shares Chronic lymphocytic leukaemia and the tag nci-list.